HER2陽性乳がんの世界市場レポート 2025年

HER2陽性乳がん市場規模は、今後数年で力強い成長が見込まれます。2029年には144億1,000万米ドルに成長し、CAGRは7.08%となります。今後は、非侵襲的モニタリングのためのリキッドバイオプシー需要の高まり、併用療法の採用の増加、免疫療法や新規薬剤製剤の重視の高まり、リキッドバイオプシー技術の利用拡大といった要因が予測期間の成長を牽引するとみられます。さらに、専門的ながん治療センターの増加がこの成長に寄与しています。予測期間における主な動向としては、標的療法の発展、新薬の処方、免疫療法アプローチの革新、新規HER2標的療法の開発、患者層別化を改善するためのバイオマーカーの進歩などが挙げられます。

免疫療法の採用拡大がHER2陽性乳がん市場の大幅な成長を牽引すると予想されます。免疫療法は、がんを含む疾患と闘う免疫系の自然な能力を高める、あるいは改変する治療法です。免疫系ががん細胞を識別し排除する能力を強化することで効果を発揮し、従来の治療と比較して有効性の向上と副作用の軽減を実現します。HER2陽性乳がんでは、免疫療法は、身体の免疫系がHER2過剰発現がん細胞を標的として攻撃することを可能にすることで、患者の転帰を改善し、再発のリスクを低減することに役立ちます。米国がん研究協会によると、2023年にFDAは11種類の免疫チェックポイント阻害剤（ICI）を承認し、少なくとも1種類は20種類の異なるがん種および特定の分子マーカーを持つ固形腫瘍の治療に認可されました。このような免疫療法の強力な採用が、HER2陽性乳がん市場の拡大に寄与しています。

HER2陽性乳がん市場の各社は、治療効果と患者の転帰を改善する革新的な治療法の開発に注力しています。そのような治療のひとつがHER2指向性抗体薬物複合体（ADC）であり、HER2を標的とする抗体と細胞傷害性薬剤を組み合わせ、HER2陽性のがん細胞に薬剤を直接送達することで、より正確で効果的な治療を実現します。例えば、2024年1月、アストラゼネカ・インディア・ファーマ社は、第一三共と共同開発したHER2指向性ADCであるトラスツズマブ・デルクステカンを発売しました。トラスツズマブ・デルクステカンは、HER2陽性のがん細胞を標的とし、細胞傷害性薬剤をその部位に直接送達することで、より標的を絞った治療を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界HER2陽性乳がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のHER2陽性乳がん市場：成長率分析
• 世界のHER2陽性乳がん市場の実績：規模と成長, 2019-2024
• 世界のHER2陽性乳がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界HER2陽性乳がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のHER2陽性乳がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 化学療法
• 内分泌療法
• 免疫療法
• その他の治療の種類
• 世界のHER2陽性乳がん市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• その他の投与経路
• 世界のHER2陽性乳がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のHER2陽性乳がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のHER2陽性乳がん市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HER2阻害剤（トラスツズマブ、ペルツズマブ）
• チロシンキナーゼ阻害剤（TKI）
• 抗体薬物複合体（ADC）
• 低分子阻害剤
• 世界のHER2陽性乳がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン系化学療法
• タキサン系化学療法
• プラチナ製剤化学療法
• 併用化学療法レジメン
• 世界のHER2陽性乳がん市場内分泌療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• エストロゲン受容体拮抗薬
• エストロゲン除去療法
• 世界のHER2陽性乳がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤（PD-1/PD-L1阻害剤）
• 免疫調節のためのモノクローナル抗体
• がんワクチン
• 世界のHER2陽性乳がん市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• 幹細胞療法
• 温熱治療
• 遺伝子治療
• 外科的介入（乳房切除術、乳房温存手術）

第7章 地域別・国別分析

• 世界のHER2陽性乳がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のHER2陽性乳がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• HER2陽性乳がん市場：競合情勢
• HER2陽性乳がん市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis International AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co. Ltd.
• Incyte Corporation
• BioNTech SE
• MacroGenics Inc.
• CStone Pharmaceuticals Co. Ltd.
• Sorrento Therapeutics Inc.
• Syndax Pharmaceuticals Inc.
• Fate Therapeutics Inc.
• Ambrx Biopharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• HER2陽性乳がん市場2029：新たな機会を提供する国
• HER2陽性乳がん市場2029：新たな機会を提供するセグメント
• HER2陽性乳がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

HER2-positive breast cancer is a form of breast cancer distinguished by an excess of the human epidermal growth factor receptor 2 (HER2) protein. This protein accelerates the growth of cancer cells and is present in about 15-20% of breast cancer cases. Generally, HER2-positive breast cancer tends to be more aggressive compared to HER2-negative types but can be treated using targeted therapies that block HER2 activity.

The primary treatment options for HER2-positive breast cancer include targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other methods. Targeted therapy is a treatment that specifically targets certain molecules, such as proteins or genes that drive cancer growth, while minimizing damage to healthy cells. These medications can be administered through different methods, including intravenous, oral, and other routes. They are distributed through various outlets such as hospital pharmacies, retail pharmacies, and online platforms, and are utilized by different end users such as hospitals, home care services, specialty clinics, and more.

The HER2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2- positive breast cancer market statistics, including the HER2- positive breast cancer industry global market size, regional shares, competitors with the HER2- positive breast cancer market share, detailed HER2- positive breast cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the HER2- positive breast cancer industry. This HER2- positive breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The HER2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.34%. The growth observed during the historical period can be linked to factors such as the increasing rates of early detection and diagnosis, greater awareness of HER2-positive subtypes, rising investments in research and development, the growing adoption of precision medicine, and a heightened focus on enhancing patient outcomes.

The HER2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.41 billion in 2029 at a compound annual growth rate (CAGR) of 7.08%. Looking ahead, growth in the forecast period is expected to be driven by factors such as the rising demand for liquid biopsy for non-invasive monitoring, the increasing adoption of combination therapies, a growing emphasis on immunotherapies and novel drug formulations, and the expanding use of liquid biopsy techniques. Additionally, the rising number of specialized cancer treatment centers is contributing to this growth. Key trends in the forecast period include advancements in targeted therapies, new drug formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and progress in biomarkers to improve patient stratification.

The growing adoption of immunotherapy is expected to drive significant growth in the HER2-positive breast cancer market. Immunotherapy is a treatment that boosts or modifies the immune system's natural ability to fight diseases, including cancer. It works by enhancing the immune system's capacity to identify and eliminate cancer cells, offering improved efficacy and fewer side effects compared to traditional treatments. For HER2-positive breast cancer, immunotherapy helps by enabling the body's immune system to target and attack HER2-overexpressing cancer cells, improving patient outcomes and reducing the risk of recurrence. According to the American Association for Cancer Research, in 2023, the FDA approved 11 immune checkpoint inhibitors (ICIs), with at least one authorized for the treatment of 20 different cancer types and for any solid tumor with specific molecular markers. This strong adoption of immunotherapy is helping to expand the HER2-positive breast cancer market.

Companies in the HER2-positive breast cancer market are focused on developing innovative therapies to improve treatment efficacy and patient outcomes. One such therapy is HER2-directed antibody-drug conjugates (ADCs), which combine antibodies targeting HER2 with cytotoxic drugs, delivering the drug directly to HER2-positive cancer cells for more precise and effective treatment. For example, in January 2024, AstraZeneca India Pharma Ltd. launched Trastuzumab deruxtecan, a HER2-directed ADC developed in collaboration with Daiichi Sankyo. Trastuzumab deruxtecan targets HER2-positive cancer cells and delivers a cytotoxic drug directly to the site, offering a more targeted approach to treatment.

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired the rights to Zion Pharma's lead program, ZN-A-1041, for an undisclosed amount. This acquisition aims to accelerate the development and commercialization of ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor designed to treat brain metastases in HER2-positive breast cancer patients. Zion Pharma, based in China, specializes in developing drugs for HER2-positive breast cancer, and this collaboration with Roche focuses on advancing treatment options for patients with brain metastases, a common complication in HER2-positive breast cancer.

Major players in the her2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2- positive breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2- positive breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Positive Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-positive breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2-positive breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2-positive breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Targeted Therapy; Chemotherapy; Endocrine Therapy; Immunotherapy; Other Treatment Types
• 2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End User
• Subsegments:
• 1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab); Tyrosine Kinase Inhibitors (TKIs); Antibody-Drug Conjugates (ADC); Small Molecule Inhibitors
• 2) By Chemotherapy: Anthracycline-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy; Combination Chemotherapy Regimens
• 3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Antagonists; Estrogen Deprivation Therapy
• 4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors); Monoclonal Antibodies for Immune Modulation; Cancer Vaccines
• 5) By Other Treatment Types: Radiation Therapy; Stem Cell Therapy; Hyperthermia Treatment; Gene Therapy; Surgical Interventions (Mastectomy, Breast Conserving Surgery)
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. HER2-Positive Breast Cancer Market Characteristics

3. HER2-Positive Breast Cancer Market Trends And Strategies

4. HER2-Positive Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2-Positive Breast Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global HER2-Positive Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global HER2-Positive Breast Cancer Market Growth Rate Analysis
• 5.4. Global HER2-Positive Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global HER2-Positive Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global HER2-Positive Breast Cancer Total Addressable Market (TAM)

6. HER2-Positive Breast Cancer Market Segmentation

• 6.1. Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemotherapy
• Endocrine Therapy
• Immunotherapy
• Other Treatment Types
• 6.2. Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• Other Route Of Administrations
• 6.3. Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End User
• 6.5. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HER2 Inhibitors (Trastuzumab, Pertuzumab)
• Tyrosine Kinase Inhibitors (TKIs)
• Antibody-Drug Conjugates (ADC)
• Small Molecule Inhibitors
• 6.6. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracycline-based Chemotherapy
• Taxane-based Chemotherapy
• Platinum-based Chemotherapy
• Combination Chemotherapy Regimens
• 6.7. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Estrogen Receptor Antagonists
• Estrogen Deprivation Therapy
• 6.8. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors)
• Monoclonal Antibodies for Immune Modulation
• Cancer Vaccines
• 6.9. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Stem Cell Therapy
• Hyperthermia Treatment
• Gene Therapy
• Surgical Interventions (Mastectomy, Breast Conserving Surgery)

7. HER2-Positive Breast Cancer Market Regional And Country Analysis

• 7.1. Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Positive Breast Cancer Market

• 8.1. Asia-Pacific HER2-Positive Breast Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Positive Breast Cancer Market

• 9.1. China HER2-Positive Breast Cancer Market Overview
• 9.2. China HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Positive Breast Cancer Market

• 10.1. India HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Positive Breast Cancer Market

• 11.1. Japan HER2-Positive Breast Cancer Market Overview
• 11.2. Japan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Positive Breast Cancer Market

• 12.1. Australia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Positive Breast Cancer Market

• 13.1. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Positive Breast Cancer Market

• 14.1. South Korea HER2-Positive Breast Cancer Market Overview
• 14.2. South Korea HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Positive Breast Cancer Market

• 15.1. Western Europe HER2-Positive Breast Cancer Market Overview
• 15.2. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Positive Breast Cancer Market

• 16.1. UK HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Positive Breast Cancer Market

• 17.1. Germany HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Positive Breast Cancer Market

• 18.1. France HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Positive Breast Cancer Market

• 19.1. Italy HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Positive Breast Cancer Market

• 20.1. Spain HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Positive Breast Cancer Market

• 21.1. Eastern Europe HER2-Positive Breast Cancer Market Overview
• 21.2. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Positive Breast Cancer Market

• 22.1. Russia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Positive Breast Cancer Market

• 23.1. North America HER2-Positive Breast Cancer Market Overview
• 23.2. North America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Positive Breast Cancer Market

• 24.1. USA HER2-Positive Breast Cancer Market Overview
• 24.2. USA HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Positive Breast Cancer Market

• 25.1. Canada HER2-Positive Breast Cancer Market Overview
• 25.2. Canada HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Positive Breast Cancer Market

• 26.1. South America HER2-Positive Breast Cancer Market Overview
• 26.2. South America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Positive Breast Cancer Market

• 27.1. Brazil HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Positive Breast Cancer Market

• 28.1. Middle East HER2-Positive Breast Cancer Market Overview
• 28.2. Middle East HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Positive Breast Cancer Market

• 29.1. Africa HER2-Positive Breast Cancer Market Overview
• 29.2. Africa HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

• 30.1. HER2-Positive Breast Cancer Market Competitive Landscape
• 30.2. HER2-Positive Breast Cancer Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis International AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Boehringer Ingelheim GmbH
• 31.7. Daiichi Sankyo Co. Ltd.
• 31.8. Incyte Corporation
• 31.9. BioNTech SE
• 31.10. MacroGenics Inc.
• 31.11. CStone Pharmaceuticals Co. Ltd.
• 31.12. Sorrento Therapeutics Inc.
• 31.13. Syndax Pharmaceuticals Inc.
• 31.14. Fate Therapeutics Inc.
• 31.15. Ambrx Biopharma Inc.

32. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

34. Recent Developments In The HER2-Positive Breast Cancer Market

35. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

• 35.1 HER2-Positive Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 HER2-Positive Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 HER2-Positive Breast Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer